E80.29
BillableOther porphyria
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is E80.29 an HCC code?
Yes. E80.29 maps to Glycogen/Amino-Acid/Other Metabolic Disorders under the CMS-HCC V28 risk adjustment model (and Other Significant Endocrine and Metabolic Disorders under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for E80.29
For E80.29 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed E80.29 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
E80.29 is the ICD-10-CM diagnosis code for other porphyria. A rare inherited metabolic disorder affecting the body's ability to produce heme, causing various types of porphyria with symptoms like abdominal pain, neurological problems, or skin sensitivity. E80.29 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering metabolic disorders (e70-e88).
Under the CMS-HCC V28 risk adjustment model, E80.29 maps to Glycogen/Amino-Acid/Other Metabolic Disorders (HCC 50) with a community, non-dual, aged base RAF weight of 0.289. Under the older CMS-HCC V24 model, E80.29 maps to Other Significant Endocrine and Metabolic Disorders (HCC 23) with a community, non-dual, aged base RAF weight of 0.230. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Specify the type of porphyria when documented (acute intermittent, variegate, etc.) as E80.29 is for unspecified or other types. Because E80.29 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for E80.29 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Specify the type of porphyria when documented (acute intermittent, variegate, etc.) as E80.29 is for unspecified or other types
- •Review clinical documentation for acute attacks versus chronic manifestations to ensure accurate coding
Clinical Significance
Other porphyria captures porphyria types not individually coded, including variegate porphyria (VP), hereditary coproporphyria (HCP), and other rare forms. VP and HCP are dual porphyrias causing both acute neurovisceral attacks AND photosensitive skin disease, making them clinically distinct from both AIP (acute only) and PCT (cutaneous only).
Documentation Requirements
- ✓Specific porphyria type documented (variegate porphyria, hereditary coproporphyria, or other named type)
- ✓Confirmatory biochemical testing: specific porphyrin and porphyrin precursor patterns
- ✓Genetic testing if available (PPOX gene for VP, CPOX gene for HCP)
- ✓Clinical manifestations: acute attacks, skin involvement, or both
- ✓Trigger avoidance plan and safe medication list
- ✓Current management: hemin for acute attacks, sun protection for skin involvement